DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1047120
Title:
Targeting B7x and B7-H3 as New Immunotherapies for Prostate Cancer
Descriptive Note:
Technical Report,01 Sep 2014,31 Aug 2017
Corporate Author:
Albert Einstein College of Medicine, Inc Bronx United States
Report Date:
2017-11-01
Pagination or Media Count:
92.0
Abstract:
We have made excellent progress during the three-year funding period, as evidenced by eight publications. We have shown the mechanisms by which B7x inhibits T cell function and promotes prostate cancer progress. We have solved structure of B7xIgV function domain and developed new mAbs to the IgV domain for a new cancer immunotherapy targeting B7x. Similarly, we developed new mAbs to the IgV domain of B7-H3 and are in the process of developing new cancer immunotherapy targetingB7-H3. We have discovered HHLA2 and TMIGD2 as the newest members of the B7-CD28 immune checkpoint family and further showed HHLA2 was highly expressed in human prostate cancer, which provided a potential new therapeutic target for human prostate cancer and other cancers as well.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE